NSW Opens RNA Manufacturing Hub for Vaccines and Cancer Therapies

New South Wales (NSW) has opened a $96 million RNA research and pilot manufacturing facility at Macquarie University, a move aimed at strengthening Australia’s ability to develop vaccines and advanced therapies locally.

The new hub will produce messenger RNA (mRNA), synthetic RNA, lipid nanoparticles, and plasmid DNA on a small scale.

The aim is to support clinical trials of new RNA-based vaccines, cancer therapies, genetic disease treatments, and other therapies for rare genetic diseases.

State and industry leaders say the investment is designed to reduce reliance on overseas manufacturing, a vulnerability exposed during the COVID-19 pandemic.

“The COVID-19 pandemic underscored an urgent need for Australia to rapidly develop and manufacture vaccines and therapeutics,” the NSW government said in a statement.

“In addition to vaccines, the applications of RNA technology are diverse, ranging from treatments for cancers and rare genetic diseases to pest‑control solutions for agricultural use.”

Health Minister Ryan Park described the facility as “a major step forward for the future of healthcare in NSW,” while Medical Research Minister David Harris said it was important to provide “sovereign capability” to develop, test, and manufacture life-saving treatments in NSW.

RNA Australia CEO Paul McDonald said establishing a RNA manufacturing hub in NSW would retain local talent by giving researchers access to advanced manufacturing infrastructure.

“We are providing the infrastructure to realise life-saving medicinal breakthroughs right here in our own backyard,” he said.

Macquarie University vice-chancellor Bruce Dowton said the facility was opening at a time of “extraordinary global momentum in biomedical science.”

United States Moving in Opposite Direction

While NSW is celebrating the opening of its new RNA facility to advance local mRNA and RNA based technologies, the United State is moving in the opposite direction.

Under U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., the U.S. government is cancelling around $500 million in funding for mRNA vaccine development and scale back related work in existing contracts.

Kennedy has argued against continued heavy investment in mRNA technology for respiratory vaccines.

“Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them,“ Kennedy said.

“That’s why we’re moving beyond the limitations of mRNA and investing in better solutions,” he said.